← Back to blog

Medical Device Regulatory Strategy: A U.S. Guide for Innovators

November 4, 2026
Medical Device Regulatory Strategy: A U.S. Guide for Innovators

A medical device regulatory strategy is an early, written plan for how your device reaches the U.S. market: which FDA pathway you will use, what evidence it needs, how long each step takes and what it costs. Build it before you commit to a design, a license or a funding round, because the pathway you choose shapes everything that comes after it.

This guide is for researchers, university teams and founders turning a device idea into a product. It follows the order FDA itself uses: define the device, classify it, pick a pathway, plan the evidence, schedule the submissions, and prepare for life after clearance.

Techtransferadvisors
Plan Your Device’s Path to Market
Tech Transfer Advisors helps innovators navigate regulatory compliance and connect medical device research with commercialization strategy.
Explore commercialization support

TL;DR

  • A regulatory strategy is a plan for the FDA pathway, milestones, time, evidence and cost, and it should sit alongside your engineering, IP, reimbursement and fundraising plans.
  • Everything starts with intended use and indications for use. Classification, and therefore the pathway, depends on both.
  • FDA sorts devices into Class I, II and III. Class II usually goes through 510(k), Class III generally needs a PMA, and novel low-to-moderate-risk devices may use De Novo.
  • Plan testing, clinical evidence, quality-system work and postmarket duties from day one, and use FDA's early feedback mechanisms for novel technology.
  • A credible regulatory plan makes licensing terms, startup formation and investor conversations easier to defend.

Table of Contents

What a regulatory strategy is, and why it matters for research innovations

Picking a pathway is only part of it. An early regulatory strategy lays out the FDA route, the milestones, the time, the evidence and the costs, and ties them to other innovation strategies. The payoff is a realistic development and fundraising roadmap instead of a guess.

The same academic chapter points out that the regulatory burden differs by FDA pathway. It also says regulatory milestones should be integrated with engineering, R&D, manufacturing, customers, payers, investors, reimbursement and marketing strategy. In practice this means the regulatory plan is not a compliance document that regulatory staff write at the end. It decides what you build, what you test and how much money you need.

For a university lab, this matters earlier than most teams expect. A prototype that works in a bench study says little about whether FDA will want a clinical trial, a predicate comparison or neither. Without that answer, a license negotiation or a startup business plan rests on unknowns.

The legal frame is simple to state. FDA says devices marketed in the U.S. are subject to the Federal Food, Drug, and Cosmetic Act and Title 21 of the Code of Federal Regulations, and that the controls and marketing pathway depend on the device's risk and on the controls needed to reasonably assure safety and effectiveness.

Step 1: Define the device and its intended use

Every pathway decision traces back to two statements you write yourself.

  • Intended use: FDA describes this as the general purpose or function of the device.
  • Indications for use: the disease or condition the device addresses and the patient population it is intended for.

FDA's classification guidance says classification depends on both, and that indications may appear in labeling or be conveyed orally during sale. That second point catches teams out. A sales pitch that stretches the claims can change the regulatory picture, so the claims you plan to make belong in the strategy document, not just on the label.

A useful working template for a research team:

  1. Describe what the device does and how it works (principle of operation, technology, energy source, materials).
  2. State who it is for and in what clinical setting.
  3. State the condition it diagnoses, treats, monitors or prevents.
  4. List the claims you would like to make, then the claims you can actually support with evidence.
  5. Note how long it is used and how it contacts the body.

A narrow first indication often gives a simpler path. You can add indications later, once the first product is on the market and generating revenue.

Step 2: Classify the device

FDA uses three risk classes:

ClassRisk levelTypical controlsTypical route to market
Class ILowestGeneral controlsOften exempt from premarket submission
Class IIModerateGeneral and special controlsCommonly 510(k)
Class IIIHighestMost extensive controls and evidenceGenerally PMA

FDA says its Product Classification Database can help you determine classification. For most devices the submission type is identified within the product classification entry, and some devices need no premarket submission at all. Searching the database for devices with a similar technology and intended use is the fastest way to see where yours is likely to land.

Two cases deserve a closer look. A Class III preamendments device may still use 510(k) if FDA has not called for PMA. And a device with no good predicate may not fit neatly into any existing classification, which is where the De Novo pathway comes in.

Step 3: Choose the FDA pathway

FDA lists 510(k), De Novo, exemption, PMA, PDP, HDE and BLA as marketing pathways. The most common submissions are 510(k), PMA, De Novo and HDE. Submission type is generally identified by classification, which is why Step 2 comes first.

PathwayWhat you must showEvidence burden
ExemptCompliance with general controlsLowest
510(k)Substantial equivalence to a legally marketed predicateModerate; clinical data only for some
De NovoReasonable assurance of safety and effectiveness for a novel deviceModerate to high; clinical data for some
PMAValid scientific evidence of safety and effectivenessHighest; almost always clinical data, typically at least one clinical trial
HDEHumanitarian use pathway for rare conditionsSpecific to the program

The deciding factors are risk, novelty and the availability of a predicate. A 510(k) strategy is a predicate strategy: you have to find a legally marketed device and demonstrate substantial equivalence. If that comparison is credible, you are likely looking at a shorter, cheaper road. If your device does something new, the strategy shifts toward De Novo or PMA, and your budget and timeline change with it.

Why the pathway belongs in your business plan

The cost gap between a 510(k) and a PMA is large enough to change how you finance the company. A PMA that needs a pivotal trial is a different fundraising story from a 510(k) supported by bench and performance testing. Choosing the route early lets you tell investors honestly how much capital each milestone takes, rather than discovering the answer after you have spent the seed round.

Step 4: Plan testing, clinical evidence and quality systems

FDA says to plan nonclinical testing based on the device's classification, principles of operation, technology and labeling. Clinical evidence is required for PMAs and HDEs and for some 510(k)s and De Novo requests. Where a study is needed, it may require an Investigational Device Exemption (IDE) and Institutional Review Board (IRB) approval, and it must follow the applicable IDE and Good Clinical Practice requirements.

Quality system work is easy to postpone and expensive to retrofit. FDA states that manufacturers of Class II and III devices, and certain Class I devices, must meet design-and-development requirements. If your lab builds prototypes without design controls, you may later struggle to show how the design evolved. Starting design documentation while the device is still a research project saves rework.

Step 4: Plan testing, clinical evidence and quality systems

Plan evidence across the lifecycle

A review by FDA staff and outside experts notes that evidence requirements can be flexible. Real-world evidence may support premarket authorizations or postmarket requirements when the data source is relevant, reliable and of adequate quality. The same review recommends discussing proposed real-world evidence and study plans with FDA in advance, potentially through a Pre-Submission.

This changes how you think about a trial budget. Instead of asking only "what must we prove before launch," ask which evidence belongs before clearance and which can be collected after, and confirm that split with the agency before you build a study around it.

Step 5: Map submissions, FDA interaction and timelines

FDA organizes U.S. commercialization into four steps: classify the device and its controls; select and prepare the premarket submission; submit and interact with FDA during review; and comply with controls such as establishment registration and device listing. A staged plan built on those steps typically includes:

  1. Classification and nonclinical testing.
  2. A Q-Submission for feedback, if your device warrants it.
  3. IDE and IRB approval, if a clinical study is needed.
  4. The marketing submission.
  5. FDA review communications, including any requests for additional information.
  6. Registration and listing. Facilities must wait for clearance or approval before registering and listing devices that need a premarket submission.

Use early FDA feedback for novel technology

The expert review describes Informational Meetings and Pre-Submissions as mechanisms for early communication with FDA. They are especially useful for novel technologies and for clarifying requirements before you commit to substantial development or clinical work. For a research team whose device does not map cleanly onto existing products, an early conversation can prevent a costly wrong turn.

What a PMA sequence looks like

FDA's framework shows a typical PMA sequence: nonclinical testing, protocol development, FDA meetings, IDE submission and approval, pilot or pivotal studies, analysis, quality-system compliance, PMA submission, review, responses to deficiencies, possible advisory panel review, inspections and a decision.

Typical sequence of PMA development and review

The regulation itself sets the clock. Under 21 CFR Part 814, FDA ordinarily decides whether a PMA is filed within 45 days of receipt, and the statutory 180-day review period begins on the filing date. The regulation also permits approval conditions, such as additional information, inspection or restrictions. In real projects, deficiency letters and study time stretch the total well past those statutory figures, so budget for the whole sequence, not just the review window.

Breakthrough designation

FDA's Breakthrough Devices Program offers a designation phase followed by expedited development and prioritized review, while preserving the standards that apply to PMA, 510(k) or De Novo authorization. If your device addresses a serious condition and may offer a meaningful advantage, ask whether the program fits. Check FDA's current program page for eligibility, because criteria and procedures can be updated.

Step 6: Plan for life after clearance

A regulatory strategy that ends at clearance is incomplete. RAPS, the regulatory affairs professional society, states in its postmarket chapter that U.S. commercialization planning must address:

  • Registration and listing
  • Complaint handling
  • FDA inspections
  • Medical device reporting
  • Tracking, where applicable
  • Recalls, corrections and removals
  • Postmarket surveillance

The same chapter says manufacturers generally report device-related deaths, serious injuries and reportable malfunctions to FDA within 30 calendar days. Events requiring immediate remedial action are reported within five working days. Whoever will be the manufacturer of record needs the people, procedures and software to meet those clocks. If a university licenses the technology to a startup, that responsibility moves with the product, so it should be part of the license discussion.

Build the budget before you build the pitch

The academic chapter on FDA planning says early regulatory work should estimate time, evidence and cost for each step, so academic entrepreneurs can plan fundraising and the capital infusions they will need. Here is a simple method:

  1. List every step from your pathway map (testing, meetings, studies, submission, quality system, postmarket setup).
  2. For each, write the evidence required, the people involved and an estimated duration.
  3. Attach a cost range, using quotes from test labs, clinical sites and consultants rather than rules of thumb.
  4. Mark which steps are gates, where a negative result would change the plan.
  5. Match funding to gates. Non-dilutive grants such as SBIR/STTR can pay for early testing, and equity can wait for steps that raise value.

Update the document after every FDA interaction. It should be a living plan.

Five regulatory mistakes that derail research teams

  • Vague intended use. If you cannot state it in two sentences, you cannot classify the device.
  • Choosing a pathway by wishful thinking. Declaring 510(k) before finding a defensible predicate leads to a surprise later.
  • Treating the quality system as paperwork. Design controls are far easier to start early than to reconstruct.
  • Designing a study FDA has not seen. For novel devices, early feedback is cheaper than a repeated trial.
  • Ignoring postmarket duties in the financial model. Complaint handling, reporting and surveillance are recurring costs.

How regulatory strategy supports licensing and startup decisions

The FDA-and-experts review says that determining the regulatory path early, engaging FDA and stakeholders during development, aligning claims and evidence with regulatory, reimbursement, IP and market factors and planning development resources reduces risk. That de-risking can support startup or partnership decisions and investment. It also identifies early communication among researchers, clinicians, industry, patients, payers and regulators as a recurring factor in successful translation.

On the commercialization side, a 2024 study in Frontiers says U.S. innovators should consider commercial, regulatory, marketing, reimbursement, IP and market strategies early. It recommends developing a target product profile, a value proposition, a market assessment and an experienced team. It also notes that researchers can commercialize through licensing, asset acquisition or startup formation, and that technology-transfer offices can support venture development.

The licensing terms should reflect the regulatory plan. A university inventor's guide explains that a license transfers IP rights for development and commercialization and may include royalties and development commitments. It adds that an option agreement can give a startup time to evaluate the opportunity and raise funding before a full license. Development milestones in a license work best when they match real regulatory gates: a Pre-Submission, a first-in-human study, a submission. Milestones set without that map can be impossible to meet, or too easy to meet to protect anyone.

Our perspective: regulatory strategy is a commercialization decision

Most research teams treat regulatory work as something to hire for after the technology is proven. We see it the other way around. The regulatory path determines how much evidence you need, how much capital you raise and what a license is worth, so it belongs in the first conversation about commercialization.

Our team has worked inside major university technology transfer offices, in startup leadership, in federal grant review and in industry commercialization. That mix shapes how we approach a device. We read the intended use, the likely pathway and the evidence burden alongside the patent position, the licensing structure and the investor story, because a decision in one area changes the others.

A practical example of what that means: a regulatory plan can tell you which first indication gives the shortest credible route to revenue, which claims to protect in the patent strategy, and which grant mechanisms, including SBIR/STTR funding, could pay for the early testing. Our work in life sciences and medical device commercialization is built around joining those pieces, and our legal work is coordinated with a dedicated IP law partner so that patent and licensing choices stay consistent with the plan.

The result we aim for is simple: a roadmap that a faculty inventor, a technology transfer office and an investor can all read and agree on.

the author

Getting help with your regulatory roadmap

If your device is moving from lab to market, we help universities, researchers and founders connect regulatory planning with IP strategy, licensing, spinout formation, go-to-market planning, investor introductions and funding strategy. Our life sciences and medical device commercialization work covers the commercial side of the questions in this guide. See our consulting services for the full list.

Techtransferadvisors

If you are comparing options for outside regulatory support, our guide to what FDA regulatory consulting covers explains how those engagements are usually scoped.

FAQ

When should I start a regulatory strategy for a medical device?

As early as you can state the device's intended use, which is often while it is still a research project. Early planning lets you estimate the time, evidence and cost of each FDA step, and that feeds directly into fundraising and licensing decisions.

Which FDA pathway is most common?

FDA names 510(k), PMA, De Novo and HDE as the most common submission types. Which one applies to you is generally set by the device's classification. Class II devices commonly use 510(k), and Class III devices generally need a PMA.

Do I need a clinical trial?

Not always. FDA says PMAs and HDEs require clinical evidence, as do some 510(k)s and De Novo requests. Where a study is required, you may need an IDE and IRB approval. Confirm your own situation with FDA, using the classification database and, for novel devices, a Pre-Submission.

What happens after FDA clears or approves the device?

You register and list your facility and device, then meet ongoing duties such as complaint handling, medical device reporting, inspections and recall procedures. Most reportable deaths, serious injuries and malfunctions are reported within 30 calendar days.

Is a regulatory strategy different from a regulatory submission?

Yes. The submission is a document sent to FDA at one point in time. The strategy is the plan that covers pathway, evidence, timing, budget and postmarket obligations, and it guides every submission you make.

Sources

Made with BabyLoveGrowth to grow your link profile